M.E. Allison & Co’s AbbVie ABBV Stock Holding History

M.E. Allison & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$601K	Sell	2,390 -50	-2%	-$10.8K	0.35%	79
2026 Q1	$520K	Hold	2,440	–	–	0.34%	78
2025 Q4	$558K	Sell	2,440 -50	-2%	-$11.4K	0.38%	69
2025 Q3	$577K	Sell	2,490 -19	-0.8%	-$3.87K	0.4%	66
2025 Q2	$466K	Buy	2,509 +1,110	+79%	+$206K	0.37%	68
2025 Q1	$293K	Buy	+1,399	New	+$272K	0.29%	104

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

M.E. Allison & Co's ABBV Position: Q2 2026 in Review

M.E. Allison & Co reduced its AbbVie (ABBV) stake by 2% in Q2 2026, selling an estimated $10.8K and leaving 2,390 shares worth $601K. The position accounts for 0.35% of the portfolio, ranked #79.

M.E. Allison & Co first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

M.E. Allison & Co held 2,390 shares of AbbVie worth $601K as of Q2 2026.
M.E. Allison & Co sold 50 AbbVie shares in Q2 2026, an estimated $10.8K.
AbbVie made up 0.35% of M.E. Allison & Co's portfolio in Q2 2026, its #79 holding.
M.E. Allison & Co first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on M.E. Allison & Co's 13F filing for Q2 2026, filed 7 Jul 2026.